Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL138757 | 0.84 | GRM5 (0.46) | ADRA1A | |
| SCHEMBL30419444 | 0.76 | HSD11B1 (0.43) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL7157630 | 0.76 | HSD11B1 (0.43) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL31221400 | 0.70 | GRIN1 (0.44) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL15862755 | 0.70 | GRIN1 (0.47) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL626328 | 0.70 | GRIN1 (0.44) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL21246371 | 0.70 | MAP3K12 (0.41) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL6203456 | 0.69 | GRIN1 (0.50) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL6181910 | 0.69 | GRIN1 (0.50) | HSD11B1ADRA1APRKCAPTPN2HTR7 | |
| SCHEMBL29460874 | 0.69 | HSD11B1 (0.38) | HSD11B1ADRA1APRKCAPTPN2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2590985-B1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD (IE) | 2014-05-14 | — | — | EP | disclosed |
| US-8580962-B2 | Spiroheterocyclic compounds as mGlu5 antagonists | RECORDATI IRELAND LTD. (IT) | 2013-11-12 | — | — | US | disclosed |
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | RECORDATI IRELAND LTD. (IT) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059015-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS AS MGLU5 ANTAGONISTS | GRM5, GPR65, GRIK5 | HSD11B1 3157/4885ADRA1A 677/4885PRKCA 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.